Atezolizumab for the treatment of non-small cell lung cancer.

abstract：:Drug-induced liver injury (DILI) is a common form of adverse drug reaction seen within the clinic. Sensitive, specific and non-invasive biomarkers of liver toxicity are required to help diagnose hepatotoxicity and also to identify safety liabilities during drug development. Limitations exist in the current gold standa...

journal_title：Expert review of clinical pharmacology

authors： Hornby RJ,Starkey Lewis P,Dear J,Goldring C,Park BK

更新日期：2014-05-01 00:00:00

abstract：:Chagas disease is the highest impact parasitic disease in the Americas but often goes untreated due to the shortcomings of currently available therapeutics. Thus there is an urgent need for new treatment options and growing interest in drug development for the infection. This review summarizes some of the recent advan...

journal_title：Expert review of clinical pharmacology

authors： Bustamante JM,Tarleton RL

更新日期：2014-05-01 00:00:00

abstract：:Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review ...

journal_title：Expert review of clinical pharmacology

authors： Jaleel T,Elmets C,Weinkle A,Kassira S,Elewski B

更新日期：2016-01-01 00:00:00

abstract：:Pregnancy represents a major challenge in the management of patients with systemic lupus erythematosus, with substantial risks to both mother and baby. Over the past 40 years there have been major improvements in outcomes. This partly relates to the discovery of the antiphospholipid syndrome, which has transformed man...

journal_title：Expert review of clinical pharmacology

authors： Karim MY,D'Cruz DP

更新日期：2010-11-01 00:00:00

abstract：INTRODUCTION:Osteoarthritis is the most common cause of arthritis and one of the main causes of chronic pain. Although opioids are frequently employed for chronic pain treatment, their usage for osteoarthritis pain remains controversial due to the associated adverse effects. Most guidelines reserve their use for refrac...

journal_title：Expert review of clinical pharmacology

authors： Ruiz Iban MA,Benavides J,Forero JP,Bittelman S,Martinez R,Mite MA,Diaz Heredia J,Ulloa S,Lizárraga Ferrand MM

更新日期：2018-01-01 00:00:00

abstract：:Novel pharmaceutical advances in postoperative pain management include both non-opioid adjuvants as well as opioid analgesics. Optimizing postoperative analgesics includes improving onset of action, matching duration of analgesia to the setting of use, and minimizing adverse events. To improve on the current standard ...

journal_title：Expert review of clinical pharmacology

authors： Palmer P

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Joint hypermobility (JH) is the hallmark of many hereditary soft connective tissue disorders, including Ehlers-Danlos syndromes and related disorders, disorders of the TGFβ-pathway, lateral meningocele syndrome, arterial tortuosity syndrome, and cutis laxa syndromes. Contemporary practice separates individ...

journal_title：Expert review of clinical pharmacology

authors： Baban A,Castori M

更新日期：2018-07-01 00:00:00

abstract：:Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

journal_title：Expert review of clinical pharmacology

authors： Ahmed SR,Petersen E,Patel R,Migden MR

更新日期：2019-10-01 00:00:00

abstract：:RNAi is a powerful gene silencing process that holds great promise in cancer therapy by the use of siRNA. The aim of this review is to give an outline on different approaches to deliver siRNA and to describe the advantages and disadvantages of these systems. The prospects for siRNA are to be substantially better than ...

journal_title：Expert review of clinical pharmacology

authors： Ali HM,Urbinati G,Raouane M,Massaad-Massade L

更新日期：2012-07-01 00:00:00

abstract：:Contraceptive management in women with epilepsy is critical owing to the potential maternal and fetal risks if contraception or seizure management fails. This article briefly describes the pharmacokinetic interactions between antiepileptic drugs (AEDs) and hormonal contraceptives and the rational strategies that may o...

journal_title：Expert review of clinical pharmacology

authors： Reddy DS

更新日期：2010-03-01 00:00:00

abstract：:Research on the specific effects of sex and gender on pharmacokinetics and pharmacodynamics, as well as safety profile tolerability and drug efficacy, of medications remain meager because female animals and women have only recently been included in the pharmacological domain. To date, the influence of sex and gender o...

journal_title：Expert review of clinical pharmacology

authors： Franconi F,Campesi I

更新日期：2014-07-01 00:00:00

abstract：:Methotrexate is an antifolate agent used in the treatment of various cancers and some autoimmune diseases. In oncology, methotrexate is frequently administered at a high dose (>1 g/m(2)) and comes with various procedures to reduce the occurrence of toxicity and particularly to ensure optimal renal elimination. Drug-dr...

journal_title：Expert review of clinical pharmacology

authors： Levêque D,Santucci R,Gourieux B,Herbrecht R

更新日期：2011-11-01 00:00:00

abstract：:Chronic diarrhea remains a common condition that affects people infected with human immunodeficiency virus (HIV) despite the widespread use of potent antiretroviral therapy. It is important that providers control this condition, as the persistence of diarrhea affects the quality of life of patients and may contribute ...

journal_title：Expert review of clinical pharmacology

authors： Castro JG,Chin-Beckford N

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased e...

journal_title：Expert review of clinical pharmacology

authors： Baron J,Wang ES

更新日期：2018-06-01 00:00:00

abstract：:Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

journal_title：Expert review of clinical pharmacology

authors： Esposito A,Viale G,Criscitiello C,Curigliano G

更新日期：2019-01-01 00:00:00

abstract：INTRODUCTION:Dapsone is a sulfone drug used to treat infectious conditions and also numerous dermatologic diseases. Fixed drug eruption is a distinctive adverse cutaneous reaction associated with the initial administration and subsequent delivery of a specific agent. Areas covered: The authors preformed a literature se...

journal_title：Expert review of clinical pharmacology

authors： Garcia D,Cohen PR

更新日期：2017-07-01 00:00:00

abstract：INTRODUCTION:The Pharmacokinetics/pharmacodynamics (PK/PD) relationships with cytotoxics are usually based on a steepening concentration-effect relationship; the greater the drug amount, the greater the effect. The Maximum Tolerated Dose paradigm, finding the balance between efficacy, while keeping toxicities at their ...

journal_title：Expert review of clinical pharmacology

authors： Rodallec A,Fanciullino R,Lacarelle B,Ciccolini J

更新日期：2018-06-01 00:00:00

abstract：:Inflammation plays a critical role in host defense, maintaining cellular and tissue integrity following chemical, physical and biological insults. Inflammation presents in a variety of acute and chronic disease states and can contribute to disease resolution or progression depending upon the type, magnitude and durati...

journal_title：Expert review of clinical pharmacology

authors： Cressman AM,Petrovic V,Piquette-Miller M

更新日期：2012-01-01 00:00:00

abstract：:Introduction: The placenta is a temporary and unique organ that allows for the physical connection between a mother and fetus; this organ regulates the transport of gases and nutrients mediating the elimination of waste products contained in the fetal circulation. The placenta performs metabolic and excretion function...

journal_title：Expert review of clinical pharmacology

authors： Blanco-Castañeda R,Galaviz-Hernández C,Souto PCS,Lima VV,Giachini FR,Escudero C,Damiano AE,Barragán-Zúñiga LJ,Martínez-Aguilar G,Sosa-Macías M

更新日期：2020-03-01 00:00:00

abstract：INTRODUCTION:Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination remains the standard of care for acute myeloid leukemia (AML) patients who are considered candidate for intensive and curative approaches. However, the toxicity of this regimen is high, with disappointing clinical outcomes am...

journal_title：Expert review of clinical pharmacology

authors： Megías-Vericat JE,Martínez-Cuadrón D,Sanz MÁ,Poveda JL,Montesinos P

更新日期：2019-03-01 00:00:00

abstract：:Pharmacogenomics is a rapidly developing sector of human genetics research with arguably the highest potential for immediate benefit. There is a considerable body of evidence demonstrating that variability in drug-treatment response can be explained in part by genetic variation. Subsequently, much research has ensued ...

journal_title：Expert review of clinical pharmacology

authors： Turner SD,Crawford DC,Ritchie MD

更新日期：2009-09-01 00:00:00

abstract：:Introduction: An important gap within modern medicine is the lack of enough comparative effectiveness research of marketed medicines. Low-risk pragmatic randomized controlled trials (pRCTs) are those conducted resembling usual clinical practice that poses no or minimal incremental risk compared with normal clinical pr...

journal_title：Expert review of clinical pharmacology

authors： Dal-Ré R

更新日期：2020-03-01 00:00:00

abstract：:The last decades were characterized by enormous technological advances resulting in a better understanding of disease pathologies and improvement of treatment strategies. The development of targeted drugs, whose beginning can be traced back to Paul Ehrlich's theory of the 'magic bullet' approximately 100 years ago, is...

journal_title：Expert review of clinical pharmacology

authors： Hebar A,Valent P,Selzer E

更新日期：2013-01-01 00:00:00

abstract：INTRODUCTION:Ocular dysfunctions and toxicities induced by antiepileptic drugs (AEDs) are rarely reviewed and not frequently received attention by treating physicians compared to other adverse effects (e.g. endocrinologic, cognitive and metabolic). However, some are frequent and progressive even in therapeutic concentr...

journal_title：Expert review of clinical pharmacology

authors： Hamed SA

更新日期：2019-04-01 00:00:00

abstract：:Magnetic nanoparticles (MNPs) represent a promising nanomaterial for the targeted therapy and imaging of malignant brain tumors. Conjugation of peptides or antibodies to the surface of MNPs allows direct targeting of the tumor cell surface and potential disruption of active signaling pathways present in tumor cells. D...

journal_title：Expert review of clinical pharmacology

authors： Wankhede M,Bouras A,Kaluzova M,Hadjipanayis CG

更新日期：2012-03-01 00:00:00

abstract：:Introduction: Dementia is the 7th leading cause of death that imposes a significant financial and service burden on the global population. Presently, only symptomatic care exists for cognitive loss, such as Alzheimer's disease.Areas covered: Given the advancing age of the global population, it becomes imperative to de...

journal_title：Expert review of clinical pharmacology

authors： Maiese K

更新日期：2020-01-01 00:00:00

abstract：INTRODUCTION:Diabetes mellitus is associated with increased cardiovascular disease (CVD) risk. Areas covered: Main goal of hypolipidemic treatment in diabetic patients is low-density lipoprotein cholesterol (LDL-C) lowering with the use of statins. Addition of ezetimibe is useful in diabetic patients who cannot achieve...

journal_title：Expert review of clinical pharmacology

authors： Filippatos TD,Florentin M,Georgoula M,Elisaf MS

更新日期：2017-02-01 00:00:00

abstract：:Respiratory distress syndrome (RDS) is the leading cause of neonatal morbidity and mortality in premature infants. It is caused by surfactant deficiency and lung immaturity. Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis o...

journal_title：Expert review of clinical pharmacology

authors： Jordan BK,Donn SM

更新日期：2013-03-01 00:00:00

abstract：INTRODUCTION:Osteoarthritis constitutes one of the leading causes of pain and disability worldwide with a significant impact on health-care costs. Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases. Just recently, a...

journal_title：Expert review of clinical pharmacology

authors： Angeli F,Trapasso M,Signorotti S,Verdecchia P,Reboldi G

更新日期：2018-11-01 00:00:00

abstract：:The aim of this article was to assess the efficacy and safety of apremilast in treatment of psoriatic arthritis (PsA) with meta-analysis method. We included four randomized clinical trials identified from MEDLINE, EMBASE, Cochrane Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared apremilast with place...

journal_title：Expert review of clinical pharmacology

authors： Qu X,Zhang S,Tao L,Song Y

更新日期：2016-06-01 00:00:00